Pfizer Inc. (NYSE:PFE) Position Boosted by Nelson Van Denburg & Campbell Wealth Management Group LLC

Share on StockTwits

Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,821 shares of the biopharmaceutical company’s stock after purchasing an additional 5,727 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Pfizer were worth $2,808,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. Evolution Wealth Advisors LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $34,000. IMA Wealth Inc. boosted its holdings in shares of Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 477 shares during the period. Winch Advisory Services LLC boosted its holdings in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 336 shares during the period. Financial Gravity Wealth Inc. boosted its holdings in shares of Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares during the period. Finally, Karp Capital Management Corp acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $53,000. Institutional investors own 71.68% of the company’s stock.

In other news, Director Scott Gottlieb purchased 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were bought at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, EVP Frank A. Damelio sold 153,184 shares of Pfizer stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the completion of the transaction, the executive vice president now directly owns 489,647 shares in the company, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

PFE has been the subject of several research reports. ValuEngine cut shares of Pfizer from a “hold” rating to a “sell” rating in a report on Saturday, September 14th. Goldman Sachs Group restated a “buy” rating and set a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. UBS Group restated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Morgan Stanley decreased their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. raised their price target on shares of Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $45.88.

PFE traded up $0.41 during midday trading on Friday, hitting $36.93. 11,861,348 shares of the company’s stock traded hands, compared to its average volume of 19,822,398. The company has a market cap of $201.88 billion, a PE ratio of 12.31, a price-to-earnings-growth ratio of 2.90 and a beta of 0.65. The stock’s fifty day simple moving average is $36.04 and its 200-day simple moving average is $40.59. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a one year low of $33.97 and a one year high of $46.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 earnings per share. On average, research analysts expect that Pfizer Inc. will post 2.81 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd were given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.90%. The ex-dividend date of this dividend was Thursday, August 1st. Pfizer’s payout ratio is presently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Why is the LIBOR significant?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.